DAWEX
22.4.2024 08:31:26 CEST | Business Wire | Press release
Data4Industry-X, the trusted data exchange solution for Industry, carries on its dynamics to bring the most comprehensive and flexible solution on the market for industrial organizations aiming at boosting competitiveness and minimizing carbon footprint. Recognized as a Gaia-X Lighthouse project and contributing to the Manufacturing-X initiative, the Data4Industry-X solution is designed to accelerate data & information exchange between global organizations, subsidiaries and suppliers by leveraging the most advanced, secure and compliant data exchange technology on the market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240421440918/en/
Supported by the AIF (Alliance pour l’industrie du futur), and initially responding to the power generation and automotive markets, Data4Industry-X gathers technological & industrial expertise from Dawex, Schneider Electric, Valeo, CEA, and Prosyst, in order to deliver broad cross-border, cross-company, cross-factory industrial data exchanges.
Industrial organizations with plants, shop floors and suppliers, spread across the globe with decentralized manufacturing, are concerned by their ability to bring innovations and operational efficiencies to increase competitiveness, while reducing CO2 emissions to meet and report on their sustainability obligations.
With the objective to support the digital transformation of all industry stakeholders and create a compelling industry data ecosystem encompassing all sizes of organizations, Data4Industry-X solution relies on Dawex Data Exchange technology. The solution is based on open and cloud-agnostic architecture, to deliver a trusted, secure, sovereign and compliant data exchange environment that implements the Gaia-X de facto standards. Powered by this technology, the Data4Industry-X solution will use the Eclipse Dataspace Component framework to facilitate interoperability between data spaces. Additionally, thanks to the UDC (Unified Data Collector) Prosyst solution, Data4Industry-X interfaces with OPC UA protocol to retrieve industrial data and exchange them at scale with the broad ecosystem.
By relying on technological and industrial expertise, Data4Industry-X becomes the most agnostic, flexible and advanced data exchange solution for Industry, designed in compliance with the new European data regulations, such as the Data Act and the Data Governance Act, capable of operating in any industrial situation, with all types of companies.
The Data4Industry-X solution will bridge the entire industry data ecosystem by enabling large and small organizations in all sectors to exchange, distribute and valorize industrial data, securely, to ultimately improve operational efficiency and meet decarbonation objectives.
“Data4Industry-X pursues its dynamics to deploy the most advanced data exchange solution for the industry to accelerate innovation, better control carbon footprint, and gain competitive advantage thanks to data circulation.” said Laurent Lafaye, co-CEO at Dawex. “Data4Industry-X will ultimately empower all industry stakeholders, of all sizes, to engage into data exchange and contribute to fostering a resilient and sustainable industry ecosystem by benefiting from the full potential of data”.
Data4Industry-X is supported by the French government’s France 2030 initiative and the European program Next Generation.
About Dawex
About Schneider Electric
About Valeo
About CEA-List
About Prosyst
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240421440918/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom